AllDocs -> cancers

prostate cancer Breast and Prostate Cancer Prevention Breast Cancer What is Breast Cancer ? Abnormal cell growth in lobes or ducts of breast Breast cells grow out of control Cells clump together forming a mass Breast Mass Most breast masses are not cancerous (benign) Benign masses are not life threatening Some masses are cancerous (malignant) Breast Cancer Risk Factors Sex Age Race Alcohol consumption Diet Lifetime Exposure to Estrogen Early menarche Late menopause No pregnancies or 1st child after 30 Use of birth control pills or estrogen therapy Breastfeeding for at least 3 months appears to lower the risk of developing breast cancer by 25%. Personal and ...

Characterization of Epidemiology Data Relating to Prostate Cancer and Exposure to Atrazine July 17, 2003 Scientific Advisory Panel Page 2 2 Introduction The FIFRA Scientific Advisory Panel is being asked to review and consider the Agency’s analysis of evidence that exposure to atrazine may be associated with an increased incidence of prostate cancer in humans. The Agency’s analysis considers the currently available epidemiology data and largely focuses on a study at a manufacturing plant in Louisiana. This study , initially funded by Ciba-Geigy, later by Novartis, and now by Syngenta , has been updated a number of times over the years as more data on the mortality and incidence of disease have become available. The study was conducted by Dr. Elizabeth Delzell and her colleagues at the University of Alabama. In addition, the Agency’s analysis considers ...

PROSTATE CANCER 361 CHAPTER 17 Prostate cancer Kenneth J. Pienta, MD , Howard Sandler, MD , Javid Javidan, MD , and Martin G. Sanda, MD Prostate cancer is the most common cancer in US men. Despite the fact that this cancer will be diagnosed in an estimated 220,900 US men in the year 2003 and will lead to the death of over 28,900 men, there is no universally agreed- upon strategic plan for its diagnosis and management. Epidemiology Age The risk of developing prostate cancer begins to increase at age 50 years in white men who have no family history of the disease and at age 40 years in black men and those who have a first-degree relative (father, brother) with prostate cancer . Risk increases with age but, unlike other cancers, prostate can- cer has ...

Effective antigen cross- presentation by prostate cancer patients’ dendritic cells: implications for prostate cancer immunotherapy DE Orange 1,4 , M Jegathesan 1,4 , NE Blache`re 1 , MO Frank 1 , HI Scher 3 , ML Albert 1 & RB Darnell 1,2 * 1 Howard Hughes Medical Institute, and Laboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, USA; 2 Department of Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY USA; and 3 Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY USA Despite the potency with which dendritic cells (DCs) are able to utilize the exogenous MHC I antigen cross-presentation pathway to cross-present ...

English April 2002 [BHC-6055] 1 / 2 D E P A R T M E N T Prostate cancer : what are the treatment options? Every man has a prostate , a small gland that produces some of the fluid in semen. It is found at the base of the bladder and surrounds the urethra (the tube which takes urine from the bladder to the penis). At some time in their lives, one in ten men in Australia will be diagnosed with prostate cancer . This usually affects men after the age of 50, and becomes increasingly common over the following dec- ades. However, this cancer tends to grow slowly - most men who have it don’t die from the disease. What is prostate cancer ? It’s normal for the prostate to get bigger after middle age. This can cause symp- toms, such as needing to pass water more often. But an enlarged prostate isn’t the same as cancer . Cancer is ...

Chinese April 2002 [BHC-6055] 1 / 2 D E P A R T M E N T ½ : 8 ? Prostate cancer : what are the treatment options? ½ , 8 ¼ + q , ? , 8( 7 ) q ! ? 2 ? ½ q 8 50 ? , ? 8q% ( / – ½ ( q ½ ? ? , ½ q , àq ½ ? q / ½ / q , ½ ? q ½ ? , ? ? q ½ 8 q ½ ? , Æ Aq2 / 8ü ? q Æ : Ã : ¼ ½ q ä : X- ä + q (Brachytherapy) : ä — 8 8 ? + q / q — ä ½ q / A ?8 q( : ? ...

— T HIRD E DITION — S E P T E M B E R 2 0 0 2 Published as a public service by Prostate Cancer Fund (A special program of Project Cure) P.O. Box 96673, Washington, D.C. 20090-6673 • 1-800-716-2152 Treatment of Prostate Cancer with Natural Therapeutics MT952-REP Page 2 2 Introduction: The prostate is a gland in the male reproductive system that helps produce semen, the thick fluid that carries sperm cells. The prostate is a walnut-sized structure located beneath the bladder of males. It surrounds the upper part of the urethra. The urethra is the tube that carries urine from the bladder. Prostate function is regulated by testosterone, the male sex hormone produced primarily in the testicles. Prostate cancer represents a significant number ...

Prostate Cancer : Is Screening Right for You? • Prostate cancer is the most common cancer in men. It is the second leading cause of cancer deaths in men. • Certain men are at higher risk of prostate cancer : • African American men, men of African descent, men with a father, brother, or son with prostate cancer , and all men over 50 are at higher risk. • There are two tests that screen a man for prostate cancer . • The digital rectal exam (DRE) is where a doctor feels the prostate gland by putting a finger inside the rectum. • The PSA ( prostate specific antigen) is a blood test for prostate cancer . • The PSA is done along with a DRE to screen for prostate cancer . • The PSA test can find prostate cancer earlier than the DRE alone. • The PSA test can ...

Montreal West Island Montreal West Island Prostate Cancer Support Group April 2003 - Issue #34 Contributors EDITOR DESPERATELY NEEDED ! The Prez Sez The Prez Sez The Prez Sez Doug Potvin President The following information has been forwarded to us from Wally Seeley, Executive Director of CPCN. A brochure has been produced to go along with the Living Proof outdoor poster. These will appear in Pharmaprix pharmacies in Quebec and Shoppers Drug Mart outlets in the rest of Canada. We have been asked to help to distribute these to family physicians, clinics, libraries, etc. in Montreal. A new AstraZeneca patient booklet has been produced and these will be available in April. CPCN is hoping to recruit a bilingual French Canadian to assist efforts in the Prov- ince. If any person ...

1 Town Hall Meetings Comments and Suggestions Prostate Cancer Comments • Native American community cancers include prostate cancer . • Prostate cancer is a problem. There is screening but no money for follow up. • Prostate screenings are being funded through the tobacco settlement funding and are not connect to what a person may owe the system. No one should be refused as long as the money is there. • Johns Hopkins Hospital will not do a screen for prostate cancer if person owes money to their system. • There are eligibility criteria but because of the high rate of prostate cancer in African American men, we will screen any African American man over 45. If they have no insurance, there is no cost. If they have insurance, the funding pays for what ever the insurance does not pay. Basically it is free ...

1999 State Added Questions - Prostate Cancer Screening Only ask males greater than or equal to age 50. This next section of questions deals with prostate cancer and screening practices. Next, I'd like to ask you about the PSA or Prostate Specific Antigen blood test. This test is used by some physicians to help detect prostate cancer or to determine how well prostate cancer is responding to treatment. PRO1. Have you ever been told by a physician that you should have a PSA blood test to check for prostate cancer ? Yes 1 No 2 Don=t know/Not sure 7 Refused 9 PRO2. Have you ever had a PSA blood test? Yes 1 No Go to PRO5 2 Don=t know/Not Sure 7 Refused 9 PRO3. How long has it been since your last Prostate Specific Antigen blood test? Within the past year(0-12 months ago) 1 ...

prostate cancer By 2nd Lt. Michael Chillstrom, 59th Medical Wing public affairs [766 words] Air Force?s Wilford Hall at forefront of prostate cancer battle Leading the way in medical research, Wilford Hall Medical Center was intricately involved in a highly publicized, landmark study on the drug Finasteride?s (Proscar) ability to prevent prostate cancer . Wilford Hall was the largest site?providing roughly 10 percent of the participant population?for this extensive seven-year, nationwide study, named the Prostate Cancer Prevention Trial, or PCPT. The trial, published in the July 17 edition of ?The New England Journal of Medicine,? found a 25 percent reduction in prostate cancer occurrences for healthy males taking Finasteride. Although the findings are far short of being a cure-all answer, physicians laud the trial?s ...

8 9 With new funding from the US Army Medical Research and Materiel Command (USAMRMC), which has a mandate to ‘provide solutions to medical problems’ for the military, both on and off the battlefield, Pamela Russell and her team are expanding their research into these two areas. “The first study will investigate the role of genes thought to be involved in the spread of prostate cancer to other, more life-threatening parts of the body,” said Pamela Russell, “while the second project is concerned with new treatments for prostate cancer that seek to target cancer cells while ignoring their healthy neighbours.” Researchers already know that errors in genetic material or DNA are responsible for all cancers. Previous studies at the Oncology Research Centre have shown that additional genetic errors ...

MDACC Prostate Cancer (Page 1 of 4) (V4 5/5/01) 72 73 74 This Prostate Cancer Guideline is used as a framework for the application of individualized therapy for patients with prostate cancer at the M. D. Anderson Cancer Center. The faculty members of the Genitourinary Center apply these general guidelines to individual patients accommodating patient preference and physician experience in the context of a specific knowledge of prostate cancer . Guidelines Change Over Time - For Updates Refer to www.mdanderson.org Page 2 MDACC Prostate Cancer (Page 2 of 4) INITIAL THERAPY CLINICAL STAGE STAGING WORKUP INITIAL DIAGNOSIS Surveillance, no treatment until progression or Radiotherapy or cryosurgery or homonal ablation Radiotherapy ...

MDACC Suspicion of Prostate Cancer Positive screening exam or Urinary obstructive symptoms DRE PSA >4 ng/ml? TRUS Treat other causes of symptoms Annual DRE and PSA TRUS-guided biopsy (Sextant biopsies if no lesion on TRUS) TRUS-guided biopsy TRUS-guided biopsy DRE and PSA in 6-12 months Positive Positive for nodule Neg (V1;10/26/98;5/21/99) Neg No Yes TRUS-guided biopsy negative Refer to Prostate Cancer Practice Guideline Low grade: continue follow-up with urologist (annual DRE and PSA). High grade: repeat PSA and biopsy in 1-4 months. TRUS-guided biopsy positive for PIN TRUS-guided biopsy positive for cancer Screening: Annual DRE and PSA for men aged 50-70 yr (Begin at age 40 for African-American men and those with a ...

NOW AVAILABLE from Us Too! I NTERNATIONAL R E S O U R C E S F O R M A K I N G P R O S T A T E C A N C E R D E C I S I O N S The biggest asset to empowered patient decision making is information . Men newly diagnosed with prostate cancer may spend precious days, weeks or months searching for definitive and reliable information upon which to make a treatment option decision. For the first time there is a definitive starting point – a collection of quality and reliable information – to help the newly diagnosed navigate through a complex decision making process. In addition, this “resource kit” will also help anyone looking to learn more about prostate cancer , available treatment options as well as other medical and emotional aspects of the disease which affect every man diagnosed with prostate cancer , their spouse/partner and family! Included in this handy ...

Prostate Cancer Introduction Prostate cancer is a malignant tumor that arises in the prostate gland. As with any cancer , if it is advanced or left untreated in early stages, it can eventually spread through the blood and lymph fluid to other organs. Fortunately, prostate cancer tends to be slow growing compared to other cancers. As many as 90% of all prostate cancers remain dormant and clinically unimportant for decades. This high incidence of latent or incidental malignancy is unique to the prostate gland. Most older men eventually develop at least microscopic evidence of prostate cancer , but it often grows so slowly that, as one specialist has written, many men with prostate cancer "die with it, rather than from it." Hormones and Prostate Cancer Male hormones (androgens) play major roles in the development of prostate cancer . Some research, ...

I n this issue (page 586), 1 Linda Perron and colleagues question whether the recent decline in age-standard- ized prostate cancer mortality rates in Quebec could be attributed to screening with the serum prostate -specific antigen (PSA) test. By comparing the change in the inci- dence rate of prostate cancer between 1989 and 1993 with the change in the prostate cancer mortality rate between 1995 and 1999 in 15 birth cohorts, and in 15 regions of Quebec, the authors have elegantly shown that increased screening efforts with the PSA test were not correlated with the subsequent declining mortality rate. PSA-based screening for prostate cancer remains a con- troversial issue. The availability of presumably valid screen- ing tests and the potential success of curative treatment op- tions such as radical prostatectomy have prompted some health ...

586 JAMC • 5 MARS 2002; 166 (5) © 2002 Canadian Medical Association or its licensors Research Recherche From *the Centre de recherche en cancérologie de l’Université Laval and †the Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Quebec City, Que. This article has been peer reviewed. CMAJ 2002;166(5):586-91 ß See related article page 600 Abstract Background: Physicians have speculated that prostate -specific antigen (PSA) screen- ing may be responsible for the reduction in prostate cancer mortality observed in the late 1990s. In order to test this hypothesis, we assessed the relation between the change in prostate cancer incidence in the early 1990s, attributed largely to PSA screening, and the subsequent change in prostate cancer mortality. Methods: ...

MDS Diagnostic Services 100 International Blvd. Toronto, Ontario Canada M9W 6J6 www.mdsdx.com PSARFAL03E L e a r n M o r e A b o u t L e a r n M o r e A b o u t L A B T E S T S www.mdsdx.com Prostate Cancer P S A R a t i o Te s t i n g a n d Page 2 What’s Inside In this leaflet you will learn about a simple blood test, called the Prostate -Specific Antigen Ratio (PSA Ratio) test. This test is also referred to as a Free PSA. Managing your Health Your healthcare provider uses a variety of tests to determine your current health status. Some of these tests are performed on an annual basis and some are ordered when specific symptoms require a closer look. All of the information gained through these tests allows you and your doctor to work together, as a team, to best manage ...

Screening Prostate Cancer f o r A f r i c a n A m e r i c a n s A D e c i s i o n G u i d e Page 2 This booklet was developed by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Published in October 2003. Page 3 1 To help you understand both sides of the issue, let’s begin with the basics. Is screening right for you? The decision is yours. Some medical experts believe all men should be offered regular screening tests for prostate cancer . Other medical experts do not. Page 4 What is the prostate ? The prostate is a walnut-sized gland that only men have. It is part of the reproductive system that makes the fluid that carries sperm. As you can ...

prostate cancer The National Prostate Cancer Coalition Setting the Course for a Cure NPCC – Quick History Started in 1996 by a group of survivors, doctors and philanthropists to address the need for significant federal investments in prostate cancer research. NPCC ’ s Mission End the devastating impact of prostate cancer on men, their families and communities through awareness, outreach and advocacy PCa & BCa Deaths and Funding Growth in Prostate Cancer Cases How We Do It – Public Policy Public Policy is responsible for increasing federal funding at the agencies that conduct prostate cancer research Department of Defense National Institutes of Health/National Cancer Institute Department of Veterans Affairs Public Policy also advocates ...

prostate cancer Prostate Cancer Studies Mohamed Bidair, M.D. Diplomate, American Board of Urology Alvarado La Mesa Urology Medical Associates Prostate Cancer Research and Education Foundation Featured Speaker Series December 13, 2003 f Prostate Cancer Studies An investigational selective endothelin receptor antagonist, being developed for the treatment of prostate cancer . These patients must be status-post prostatectomy, hormone naïve, with rising PSA. Prostate Cancer Studies Open-Label Leuprolide formulation for patients with prostate cancer in need of chemical castration. A percentage of patients currently on a leuprolide castration regime can be entered in the study if dosing schedule isn’t interupted Prostate Cancer Studies A 3 Month Open Label ...

prostate cancer Diet and Stress Reduction in Advanced Prostate Cancer GORDON A. SAXE, MD, PhD UNIVERSITY OF CALIFORNIA, SAN DIEGO Rebecca and John Moores UCSD Cancer Center Dept. of Family and Preventive Medicine Primary Research Question: Can healthy dietary change, reinforced by stress reduction, slow or stop the progression of advanced prostate cancer ? Rationale Prostate cancer is the most commonly occurring cancer (other than skin cancer ) among men in the U.S. In 1995, there were 244,000 new cases and 44,000 deaths from prostate cancer in the U.S. Rationale One in six men in the U.S. will develop invasive prostate cancer in his lifetime. One in four African-American ...

Prostate Cancer Statistics UNITED STATES 220,900 28,900 168.9 33.9 Alabama 4,700 600 93.1 41.9 5 Alaska 200 † 152.2 22.6 Arizona 4,300 600 — 29.9 Arkansas 2,600 300 130.5 37.4 California 20,500 1 2,700 1 154.3 29.3 Colorado 2,600 300 156.9 30.8 Connecticut 2,800 400 165.6 31.0 Delaware 600 100 172.5 10 38.8 9 District of Columbia 600 100 256.6 1 53.7 1 Florida 15,800 2 2,100 2 — 30.1 Georgia 5,700 700 130.1 41.6 6 Hawaii 900 100 124.1 22.7 Idaho 1,100 100 ...

PROSTATE CANCER INCIDENCE AND MORTALITY IN ARIZONA 1990-1997 Arizona Department of Health Services Bureau of Public Health Statistics Office of Health Registries Arizona Cancer Registry Office of Epidemiology and Statistics 2700 North Third Street, Suite 4075 Phoenix, Arizona 85004 Ph: (602) 542-7320 June 2000 Partially Funded by the Centers For Disease Control Cooperative Agreement No. U75/CCU910675 Page 2 Jane Dee Hull , Governor State of Arizona Catherine R. Eden, Director Arizona Department of Health Services Permission to quote from or reproduce materials from this publication is granted when due acknowledgment is made Page 3 PROSTATE CANCER INCIDENCE AND MORTALITY IN ARIZONA 1990-1997 ARIZONA DEPARTMENT OF HEALTH SERVICES ...

UAMS UPDATE September 1999 University of Arkansas for Medical Sciences (501) 686-6271 . . . UAMS Medical Center To Offer Free Prostate Cancer Screenings Greene I n the past, if someone mentioned being screened for prostate cancer , Frank Milat’s response was the same as a lot of men: “What I don’t know can’t hurt me.” After undergoing a free screening at UAMS Medical Center last September, Milat knows differently. From the results of his screening, he became one of more than 209,000 American men who were diagnosed with prostate cancer in 1998. Under the care of UAMS Medical Center urologist Graham Greene, M.D., Milat has received successful treatment over the past several months. However, he never forgets the importance of that initial screening. In a continuing effort to increase prostate cancer awareness, ...

R A D I A T I O N T H E R A P Y f o r PROSTATE CANCER Non-Surgical Options Facts to Help Patients Make An Informed Decision RISK FACTORS FOR PROSTATE CANCER Incidence of prostate cancer increases with age. ¢ Median age at diagnosis in Caucasian males is 71. ¢ African-American men have the highest incidence of prostate cancer in the world. ¢ Heredity accounts for 5 to 10 percent of cases. HELPFUL WEB SITES ON PROSTATE CANCER ASTRO THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY 12500 Fair Lakes Circle, Suite 375 Fairfax, VA 22033-3882 Phone: 1-800-962-7876 • 703-502-1550 Fax: 703-502-7852 www.astro.org FACTS ABOUT PROSTATE CANCER Prostate cancer is the most common malignancy in American men. ¢ ...

Tomatoes, Lycopene, and Prostate Cancer : Progress and Promise C RAIG W. H ADLEY ,* E LIZABETH C. M ILLER ,‡ S TEVEN J. S CHWARTZ ,* AND S TEVEN K. C LINTON § ,1 *Department of Food Science and Technology; ‡Division of Hematology and Oncology, The James Cancer Hospital and Solove Research Institute; and §Division of Hematology and Oncology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio 43210 Prostate cancer has emerged as a major public health problem in nations that have an affluent culture with an aging popula- tion. The search for etiologic risk factors and an emphasis on the development of chemopreventive agents ...

Post-Test for Prostate Cancer (all answers are contained in the article) 1. The majority of men with prostate cancer have no symptoms at all which is why annual routine screening is highly recommended. Circle One - True or False 2. The Annual Digital Rectal Exam by a physician or urologist and the PSA ( Prostate Specific Antigen) blood test are the two tests for diagnosis of prostate cancer . Circle One - True or False 3. Once cancer is diagnosed more tests will be conducted to see if cancer cells have spread from the prostate to other organs, body parts, or surrounding tissue. This is called “staging”. Circle One – True or False 4. Write in your answer. List at least two symptoms that may indicate prostate disease or cancer : __ 5. Which cancer is most common in males 15-34 years of age? Circle One – Testicular Cancer , Penis Cancer , Prostate ...